drugset / Trial / NCT01393730

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

NCT01393730

Phase 2 Completed 40 enrolled Mary-Ellen Taplin, MD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic disease. This study will also help determine the side effects of the study treatment and how often they occur.

Timeline

Start
2011-09
Primary completion
2016-01
Completion
2017-03-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Dutasteride Small molecule 3.5 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications